Nigeria Receives Long-Acting HIV Prevention Injection Lenacapavir

Nigeria has officially received Lenacapavir, a long-acting HIV prevention injection, in a move described as a major step in the country’s efforts to combat the spread of HIV.

The breakthrough medication was approved by the Coordinating Minister of Health and Social Welfare, Ali Pate, with support from the Global Fund.

Lenacapavir is designed for Pre-Exposure Prophylaxis (PrEP), offering an alternative to daily oral drugs used to prevent HIV infection. The injectable treatment is administered twice a year, providing individuals at risk of contracting the virus with a more convenient option than taking medication every day.

Health experts say the new injection could significantly improve treatment adherence, particularly among people who struggle to maintain a daily drug routine.

According to Adebobola Bashorun, National Coordinator of the National HIV Viral Hepatitis and STDs Control Programme (NASCP), the arrival of Lenacapavir demonstrates Nigeria’s commitment to adopting evidence-based innovations to accelerate progress in controlling the epidemic.

Bashorun said expanding prevention options and strengthening service delivery would help reduce new infections and improve health outcomes across the country.

He added that NASCP, working alongside partners and stakeholders, would ensure the safe rollout and effective integration of Lenacapavir into Nigeria’s national HIV prevention programmes.

The drug is expected to become available in Nigeria and 119 other low- and middle-income countries at an estimated annual cost of about $40 per person, following voluntary licensing agreements with generic pharmaceutical manufacturers.

Health officials say the introduction of the long-acting injection brings Nigeria closer to achieving the goal of ending HIV as a public health threat.

165 Views